Current Wegovy users can join paid research focused on side effects through GetPaidGLP. The program asks current users to complete a short screener for matching to paid studies. Wegovy is a prescription medicine with semaglutide for chronic weight management along with diet and activity. Focus Insite says participants who qualify can take part from home or locally and earn $75–$300+ per completed study, according to its current program page.
Table of Contents
- How does GetPaidGLP work?
- Who can take part?
- Which side effects are researchers asking about?
- What should you know before applying?
- Is there another paid GLP-1 study example?
How does GetPaidGLP work?
Focus Insite operates GetPaidGLP for current Ozempic, Wegovy, or Mounjaro users. The process starts with a brief screener, followed by matching to a fitting study.
Matched participants then complete the assigned research activity and receive payment. Focus Insite says enrollment takes two to three minutes and spots fill on a rolling basis.
- Complete the 2–3 minute screener
- Get matched to a fitting study
- Participate and receive payment
Who can take part?
The program is built for adults who currently use Ozempic, Wegovy, or Mounjaro. Study descriptions explicitly mention people who have dealt with side effects.
Each study sets its own eligibility rules. Participation is voluntary and depends on meeting those rules.
- Current use of Ozempic, Wegovy, or Mounjaro
- Experience relevant to the study topic, including side effects
- Ability to take part from home or at a local site
Which side effects are researchers asking about?
Novo Nordisk lists common Wegovy effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, dyspepsia, stomach flu, and low blood sugar in type 2 diabetes, according to its NovoMedLink physician page. These day-to-day symptoms often affect dosing, meals, work, and daily plans. The FDA-approved label also warns of serious risks.
Those risks include thyroid C-cell tumors, pancreatitis, gallbladder disease, kidney injury from dehydration, hypersensitivity, and intestinal blockage or ileus, according to the FDA-approved Wegovy label. Report the timing, severity, and effect on eating and daily life when asked. Clear details help researchers match symptom patterns across users.
What should you know before applying?
Qualification is not guaranteed. Each application is screened against the needs of active studies. Focus Insite states that it is not a healthcare provider.
It also states that it does not sell data and keeps information confidential. Research participation does not replace medical care. Talk with your prescriber about ongoing or severe symptoms and next steps.
Is there another paid GLP-1 study example?
The University of Arkansas Center for Human Nutrition recruited adults over 18 who were preparing to take or had recently started Wegovy, Ozempic, Zepbound, or Mounjaro. Its paid five-week study involved four to five visits.
Those visits measured body composition, sleep, mood, and diet. That format differs from GetPaidGLP, which matches users to varied home or local studies.
